{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:13:10Z","timestamp":1787501590474,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["19JCZDJC 35300"],"award-info":[{"award-number":["19JCZDJC 35300"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800767"],"award-info":[{"award-number":["81800767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bbrc.2021.09.060","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:05:43Z","timestamp":1632776743000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The alleviating effect of sphingosine kinases 2 inhibitor K145 on nonalcoholic fatty liver"],"prefix":"10.1016","volume":"580","author":[{"given":"Yanan","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-4334","authenticated-orcid":false,"given":"Jihong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.09.060_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00109-009-0464-1","article-title":"Molecular mechanisms involved in NAFLD progression","volume":"87","author":"Malaguarnera","year":"2009","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.bbrc.2021.09.060_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1665-2681(19)32187-8","article-title":"Treatment of nonalcoholic fatty liver disease","volume":"1","author":"Angulo","year":"2002","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bbrc.2021.09.060_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrgastro.2010.21","article-title":"Pathology of nonalcoholic fatty liver disease","volume":"7","author":"Brunt","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2021.09.060_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2008.08.001","article-title":"Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)","volume":"48","author":"Musso","year":"2009","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbrc.2021.09.060_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2021.09.060_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2021.09.060_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/bs.apcsb.2019.11.003","article-title":"Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease","volume":"120","author":"Sukocheva","year":"2020","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.bbrc.2021.09.060_bib8","doi-asserted-by":"crossref","first-page":"107464","DOI":"10.1016\/j.pharmthera.2019.107464","article-title":"Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target","volume":"207","author":"Sukocheva","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2021.09.060_bib9","doi-asserted-by":"crossref","first-page":"627076","DOI":"10.3389\/fendo.2020.627076","article-title":"Role of sphingosine kinase in type 2 diabetes mellitus","volume":"11","author":"Qi","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"13","key":"10.1016\/j.bbrc.2021.09.060_bib10","doi-asserted-by":"crossref","DOI":"10.1021\/jm4011687","article-title":"Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors","volume":"57","author":"Plano","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2021.09.060_bib11","doi-asserted-by":"crossref","first-page":"225e233","DOI":"10.1021\/cb5008426","article-title":"Drugging sphingosine kinases","volume":"10","author":"Santos","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbrc.2021.09.060_bib12","doi-asserted-by":"crossref","first-page":"5124e5135","DOI":"10.1210\/en.2010-0420","article-title":"Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640","volume":"151","author":"Antoon","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbrc.2021.09.060_bib13","article-title":"Biological characterization of 3-(2-amino-ethyl)-5-[3-(4- butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2021.09.060_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbrc.2017.09.029","article-title":"3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl) -propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt\/FoxO1 pathway","volume":"493","author":"Shi","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2021.09.060_bib15","doi-asserted-by":"crossref","first-page":"52487","DOI":"10.1074\/jbc.M406512200","article-title":"Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720","volume":"279","author":"Allende","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2021.09.060_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hep.27804","article-title":"Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice","volume":"62","author":"Lee","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2021.09.060_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbadis.2018.12.012","article-title":"Sphk2-\/-mice are protected from obesity and insulin resistance","volume":"1865","author":"Ravichandran","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.bbrc.2021.09.060_bib18","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.3390\/nu7115475","article-title":"The Subtle balance between lipolysis and lipogenesis: a critical Point in metabolic homeostasis","volume":"7","author":"Saponaro","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrc.2021.09.060_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbrc.2019.08.139","article-title":"Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice","volume":"519","author":"Inamdar","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2021.09.060_bib20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","article-title":"Liver X receptor in cooperation with SREBP1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease","volume":"38","author":"Higuchi","year":"2008","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bbrc.2021.09.060_bib21","doi-asserted-by":"crossref","DOI":"10.1289\/EHP664","article-title":"Hepatic LipidAccumulation and Nrf2 expression following perinatal and peripubertal exposure to bisphenol A in a mouse model of nonalcoholic liver disease","volume":"125","author":"Shimpi","year":"2017","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.bbrc.2021.09.060_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-079X.2011.00905.x","article-title":"Melatonin alleviates lipopolysaccharide-induced hepatic SREBP1c activation and lipid accumulation in mice","volume":"51","author":"Chen","year":"2011","journal-title":"J.\u00a0Pineal Res."},{"key":"10.1016\/j.bbrc.2021.09.060_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/nu10081024","article-title":"Paeoniflorin ameliorates fructose-induced insulin resistance and hepatic steatosis by activating LKB1\/AMPK and AKT pathways","volume":"10","author":"Li","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrc.2021.09.060_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/antiox10040565","article-title":"Lingonberry improves non-alcoholic fatty liver disease by reducing hepatic lipid accumulation, oxidative stress and inflammatory response","volume":"10","author":"Madduma Hewage","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bbrc.2021.09.060_bib25","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.celrep.2014.08.028","article-title":"HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression","volume":"8","author":"Huang","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2021.09.060_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","article-title":"Roles of PPARs in health and disease","volume":"405","author":"Kersten","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2021.09.060_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.aquaculture.2013.06.003","article-title":"Hepatic triacylglycerol secretion, lipid transport and tissue lipid uptake in blunt snout bream (Megalobrama amblycephala) fed high-fat diet","volume":"408\u2013409","author":"Lu","year":"2013","journal-title":"Aquaculture"},{"key":"10.1016\/j.bbrc.2021.09.060_bib28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI6223","article-title":"Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting","volume":"103","author":"Kersten","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.bbrc.2021.09.060_bib29","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.96.13.7473","article-title":"A\u00a0critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders","volume":"96","author":"Leone","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.09.060_bib30","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.27592","article-title":"Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression","volume":"61","author":"Nagahashi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2021.09.060_bib31","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.dld.2019.03.020","article-title":"The role of sphingosine kinase 2 in alcoholic liver disease","volume":"51","author":"Kwong","year":"2019","journal-title":"Dig. Liver Dis."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21013607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21013607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:41:50Z","timestamp":1762094510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21013607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":31,"alternative-id":["S0006291X21013607"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.09.060","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The alleviating effect of sphingosine kinases 2 inhibitor K145 on nonalcoholic fatty liver","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.09.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}